CORONA Remedies Delivers Robust Start to FY27: Revenue Jumps 21.9% as PAT Grows 30.1%
Ahmedabad | July 31, 2026CORONA Remedies Limited, a leading India-focused pharmaceutical company, announced its unaudited financial results for the first quarter of Fiscal Year 27 (Q1FY27). The company reported strong revenue growth and resilient margins, driven by focused brand building initiatives and enhanced operational efficiencies.
The company recorded revenue from operations at ₹422.4 Cr for Q1FY27, marking a significant 21.9% year-on-year (Y-o-Y) increase. Profit After Tax (PAT) also saw robust growth, reaching ₹60.1 Cr, or a 30.1% Y-o-Y rise. PAT margins improved to 14.2%, reflecting an increase of 90 basis points (bps) compared to Q1FY26.
The financial performance highlights the company's steady progress across key metrics:
| Particulars (₹ in Cr) | Q1FY27 | Q1FY26 | Y-o-Y % Growth |
|---|---|---|---|
| Revenue from Operations | 422.4 | 346.5 | 21.9% |
| EBITDA | 93.1 | 69.8 | 33.5% |
| EBITDA Margin | 22.0% | 20.1% | 190 bps |
| Profit After Tax | 60.1 | 46.2 | 30.1% |
| Profit After Tax Margin | 14.2% | 13.3% | 90 bps |
Key Operational and Market Highlights
CORONA Remedies reported several key business achievements during the quarter that underscore its market position and operational strength.The company demonstrated consistent growth by ranking among the fastest-growing companies in the top 30 firms of IPM for six consecutive months, surpassing the market by 1.9 months as per MAT June'26 data. Furthermore, CORONA improved its market standing, rising three places to reach 26th rank as per MAT June'26, up from 29th in MAT June'25.
In therapy leadership, CORONA stands at the 5th rank in Gynaecology, reflecting its commitment to the segment.
Operational expansion and integration also featured prominently:
- Facility Inauguration: The company inaugurated and initiated commercialization of its EU-GMP approved Female Hormone Manufacturing Facility in Ahmedabad on June 30, 2026.
- Brand Integration: CORONA has begun the smooth integration of Wokadine, an acquired brand, across supply and distribution channels.
Management Commentary
Commenting on the Q1FY27 results, Nirav K. Mehta, Managing Director & CEO of CORONA Remedies Limited, stated that the quarter highlights the company's commitment to consistent growth through operational excellence and brand building.He noted that the robust revenue growth and market ranking improvements were positive outcomes of existing strategies. Mr. Mehta added that the management remains focused on core therapies such as Women's Healthcare, Cardio-diabetes, Pain Management, and Urology. The company is also strengthening its focus in the Infertility and Biosimilar segments.
About CORONA Remedies Limited
Founded in 2004, CORONA Remedies Limited is an India-focused pharmaceutical company engaged in the development, manufacturing, and marketing of products across crucial therapeutic areas including women's healthcare, cardio-diabetes, pain management, and urology. The company operates WHO-GMP/EU GMP certified manufacturing facilities and maintains strong innovation capabilities through its DSIR-approved R&D centers.CORONA Stock Price Movement
Today, CORONA Remedies Limited shares gained by 0.43% as it settled at ₹2098.8. The equity finished strongly, having reached a daily high of ₹2136 amid active trading volume totaling 18,140 shares today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.